Logo Image
|Videos|October 4, 2019

Carlos del Rio, MD: Infectious Disease Is a Team Sport

Carlos del Rio, MD, co-director of Emory Center for AIDS Research, discusses the collaboration across specialties that is inherent in infectious disease.

Carlos del Rio, MD, co-director of Emory Center for AIDS Research, discusses the collaboration across specialties that is inherent in infectious disease.

Interview transcript (modified slightly for readability):

Dr. del Rio: "I love how infectious disease is a team sport. Having in my team a pharmacist, going to the microlab and working with the pathologist, and the microbiologist, it really is what I love about my specialty—it's not just us the doctors that know it all doing the job. It's really us the team and how each one contributes to improving patient care and outcomes. And I find that part of infectious disease really gratifying and satisfying. So get to know your ID pharmacist, get to know your microbiologist, and work with them because you'll be a much better consultant if you do that."

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more